Pharmaceutical giant Eli Lilly is making significant changes to its diabetes medication Mounjaro, including redesigning injection pens and launching new programs to expand employer coverage of obesity drugs.

The company plans to roll out redesigned Mounjaro pens that will contain less residual medication compared to current versions. The modification addresses what some users have termed a "golden dose" practice, where patients extract additional medication from used pen injectors beyond the standard four doses.

The new pen design will effectively prevent users from accessing this fifth dose by reducing the amount of medication that remains in the device after the prescribed doses have been administered. This change represents a shift from the current pen configuration that has allowed some patients to extract extra medication.

Simultaneously, Eli Lilly has announced the launch of a new program aimed at increasing employer coverage of obesity medications in the United States. The initiative seeks to expand access to weight management drugs through workplace health insurance plans.

The timing of both announcements reflects Eli Lilly's broader strategy around Mounjaro, which has gained significant attention both as a diabetes treatment and for its weight loss effects. The medication belongs to a class of drugs that has seen tremendous demand in recent years.